Will liquid biopsies become our fluid transition to personalized immunotherapy?

Ann Oncol. 2018 Jan 1;29(1):11-13. doi: 10.1093/annonc/mdx751.

Authors

E Wauters^{1

2

3}, J Vansteenkiste^{1

2

3}

Affiliations

¹ Respiratory Oncology Unit (Pneumology), University Hospital KU Leuven, Leuven, Belgium.
² Leuven Lung Cancer Group, University Hospital KU Leuven, Leuven, Belgium.
³ Laboratory of Pneumology, Department of Chronic Diseases, Metabolism and Ageing, KU Leuven, Leuven, Belgium.

PMID: 29165546
DOI: 10.1093/annonc/mdx751

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

B7-H1 Antigen
Carcinoma, Non-Small-Cell Lung*
Humans
Immunotherapy
Leukocytes
Liquid Biopsy
Lung Neoplasms*
Neoplastic Cells, Circulating*

Substances

B7-H1 Antigen